LSN2814617
Modify Date: 2024-05-12 18:35:35
LSN2814617 structure
|
Common Name | LSN2814617 | ||
|---|---|---|---|---|
| CAS Number | 1313498-17-7 | Molecular Weight | 341.38 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C18H20FN5O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LSN2814617LSN2814617 is an orally active, potent, brain-penetrant, and selective mGlu5 (metabotropic glutamate 5) positive allosteric modulator (PAM), with EC50 values of 52 nM (Human mGlu5) and 42 nM (rat mGlu5). LSN2814617 shows wake-promoting effect. LSN2814617 can be used for schizophrenia research[1]. |
| Name | LSN2814617 |
|---|
| Description | LSN2814617 is an orally active, potent, brain-penetrant, and selective mGlu5 (metabotropic glutamate 5) positive allosteric modulator (PAM), with EC50 values of 52 nM (Human mGlu5) and 42 nM (rat mGlu5). LSN2814617 shows wake-promoting effect. LSN2814617 can be used for schizophrenia research[1]. |
|---|---|
| Related Catalog | |
| Target |
rat mGluR5:42 ± 9 nM (IC50) human mGluR5:52 ± 21 nM (IC50) |
| In Vitro | LSN2814617 (1nM-10 μM) fails to elicit responses alone in rat cortical neurons, and evokes a concentration-dependent increase in the [Ca2+]i response in AV12 cells[1]. |
| In Vivo | LSN2814617 (0.3-60 mg/kg, Orally, once) displays significant unbound brain exposure and dose-dependent occupancy of the mGlu5 receptor[1]. LSN2814617 (0-10 mg/kg, Orally, once) significantly modulates amphetamine-induced locomotor hyperactivity[1]. LSN2814617 (0-3 mg/kg, Orally, once) markedly increase wakefulness[1]. Animal Model: Male Lister Hooded rats (180-250 g, four to eight per cage)[1] Dosage: 0, 2.5, 5, and 10 mg/kg Administration: Orally, once, 60 min before amphetamine Result: Significantly modulated amphetamine hyperactivity, although a trend level decrease in hyperactivity was observed for the highest dose. At the end of the test session, from 75 to 120 min, the 10 mg/kg dose of LSN2814617 significantly increased amphetamine-induced hyperactivity. Animal Model: Adult male Wistar rats (approximately 270 g)[1] Dosage: 0, 0.3, 1, and 3 mg/kg Administration: Orally, once Result: Displayed dose-dependently increase in wakefulness immediately following oral administration; Produced 234 ± 16 min of increased wake for over 7 h in the case of 3 mg/kg. Produced dose-dependent reductions in both NREM and REM sleep. |
| References |
| Molecular Formula | C18H20FN5O |
|---|---|
| Molecular Weight | 341.38 |